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Introduction: Parkinson’s disease (PD) is a common neurodegenerative disease. In the 1960s, 
it was shown that the degeneration of dopamine producing neurons in the substantia nigra (SN) 
caused the motor features of PD. Dopamine replacement with levodopa, a dopamine precursor, 
resulted in remarkable benefit. Yet, the intermittent administration of levodopa is a major cause 
of motor complications, such as “wearing-off” of levodopa’s benefit and involuntary movements, 
known as dyskinesia. Therefore, agents that prolong levodopa’s half-life were employed, such as 
carbidopa, an aromatic amino acid decarboxylase (AADC) inhibitor, and entacapone, a catechol-
O-methyltransferase (COMT) inhibitor. The combination product carbidopa/levodopa/entacapone 
(CLE) was approved in 2003 for the treatment of PD patients.
Aims: To assess the evidence for the place of CLE in the treatment of PD.
Evidence review: CLE has a good efficacy, safety and tolerability profile, similar to that of 
entacapone taken separately with carbidopa/levodopa (CL). Compared to CL alone, it pro-
longs levodopa’s benefit, and improves the quality of life but not the motor performance in PD 
patients with nondebilitating “wearing-off” or dyskinesia. However, it increases the dyskinesia 
rate in early PD patients, and has adverse events in advanced patients with significant motor 
complications. There is insufficient evidence regarding cost-effectiveness.
Place in therapy: CLE is an attractive alternative for patients with nondisabling “wearing-off” 
or dyskinesia taking CL with or without entacapone. It cannot be recommended for early PD 
patients, as it can induce more dyskinesia than CL alone, or in any patients who seem to have 
more adverse events.
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Core evidence place in therapy summary for carbidopa/levodopa/entacapone
Outcome measure Evidence Implications
Disease-oriented evidence
UPDrS (part ii, iii, and ii+iii) Consistent Part ii improved when switched from CL to CLE 
in patient with wearing-off with or without mild 
dyskinesia.   Also improved when CLE compared 
to CL, in CL naïve early PD patients. Part iii 
scores were not different.
“Off” time (UPDrS 
question 39)
Clear Improved significantly when switched from CL to 
CLE and when compared directly in early PD.
Dyskinesia Mostly 
negative
STriDE-PD data showed higher rates 
of dyskinesia with shorter time to dyskinesia 
in patients treated with CLE.
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Scope, aims, and objectives
The combination product of levodopa, carbidopa and 
entacapone is known generically as “carbidopa/levodopa/
entacapone”, but will be referred to here as CLE. Levodopa, 
an aromatic amino acid, is the most efficacious treatment 
of Parkinson’s disease (PD) that was developed in the late 
1960s.1 It is the precursor of dopamine and crosses the blood-
brain barrier, unlike dopamine. However, only 1% of an oral 
levodopa dose reaches the brain. Approximately 70% of oral 
levodopa is metabolized by aromatic amino acid decarboxyl-
ase (AADC) in the intestinal mucosa and liver. That leads to 
increased dopamine levels in the periphery resulting in side 
effects, namely postural hypotension, nausea and vomiting.2 
Carbidopa is an inhibitor of peripheral AADC. Its addition to 
levodopa since the 1970s has decreased the incidence of the 
aforementioned side effects and increased the availability of 
levodopa to the brain. It increases the half-life of levodopa 
from 60 to 90 minutes, thus allowing for a 90% levodopa dose 
reduction to achieve the same benefit.3 Carbidopa is used in 
the USA and benserazide or carbidopa in Europe. However, 
this strategy shifts the peripheral metabolism of levodopa to 
another pathway. Catechol-O-methyltransferase (COMT) 
(Continued )
Outcome measure Evidence Implications
PDQ-39 Ambiguous improved in patients taking CLE after switching 
from CL with moderate disease, but there was no 
change in direct comparison in the early stages.
PDQ-8 Clear Better outcome in patients treated with CLE at an 
early stage of the disease.
CGi-C (investigator) Clear Equivalent improvement in both CLE, and 
carbidopa/levodopa and entacapone when 
compared with CL only, in mild to moderate 
disease severity.
Patient-oriented evidence
Discontinuation rate Clear Acceptable and equal to entacapone studies. 
Higher rate in older patients with more than 
10 years disease duration.
Adverse events Clear Expected at the rate of the previous entacapone 
studies. rated as mild to moderate by the patients.
PDQ-39 Ambiguous improved in patients taking CLE after switching 
from CL with moderate disease, but there was 
no change in direct comparison in early disease 
stages.
QOL-vAS Clear improved when switched from CL to CLE.
UPDrS part ii  Clear improved quality of life in CLE treated patients 
with mild disease severity.
CGi-C (patient) Clear Equivalent improvement in both CLE and 
carbidopa/levodopa and entacapone when 
compared with CL only, in mild to moderate 
disease severity.
Patient preference Clear Majority of patients preferred CLE over carbi-
dopa/levodopa and entacapone taken separately 
mainly due to convenience, less pill burden, better 
compliance and ease to swallow.
Economic evidence
Insufficient 
evidence
One study from the UK found favorable 
cost-effectiveness for CLE compared with CL 
treatment in PD patients with wearing-off. it is 
difficult to generalize this conclusion to different 
health-economic systems.
Abbreviations: PDQ-39, Parkinson’s Disease Questionnaire-39 (quality of life assessment tool); PDQ-8: Parkinson’s 
Disease Questionnaire-8 (quality of life); UPDRS, Unified Parkinson’s Disease Rating Scale (part II scores activities of 
daily leaving and part iii objective motor performance); CGi-C, Clinical Global impression of Change; QOL-vAS: Quality 
Of Life-visual Analog Scale; CL: carbidopa/levodopa; CLE, carbidopa/levodopa/entacapone.Core Evidence 2010:5 
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transfers the methyl group of S-adenosyl-L-methionine to 
levodopa producing 3-O-methyldopa (3-OMD), an inactive 
compound at the periphery, and 3-methoxytyramine (3-MT) 
in the brain.2,4 Entacapone is a peripheral COMT inhibitor. 
Its pharmacokinetics are unaltered by concomitant admin-
istration of levodopa/AADC inhibitor, age, gender, race or 
multiple dosing (no accumulation has been observed with 
up to 10 times daily dosing).4 Its time to peak concentration 
(tmax) is 2 hours with a half-life of 0.4 to 0.9 hours, both 
similar to levodopa. It inhibits by 65% the COMT activity 
in human erythrocytes after a dose of 200 mg. Its bioavail-
ability is between 29% and 46% and is albumin bound 
by 98%. When given together with a dose of levodopa/
carbidopa, it increases both levodopa’s half-life and its area 
under the curve (AUC) by up to 85% and 50%, respectively. 
At the same time, it does not affect the peak concentration 
(Cmax) and tmax of levodopa.4–6 Finally, it does not interact 
with compounds that are metabolized by COMT, such as 
epinephrine, isoproterenol, alpha-methyldopa, dopamine, 
dobutamide, AADC inhibitors and nadolol, or increase the 
(nor)epinephrine plasma levels when used concomitantly with 
imipramine or monoamine oxidase (MAO) A inhibitors.4 The 
clinical efficacy of entacapone was observed in prospective, 
randomized, double-blind studies on PD patients with motor 
fluctuations (levodopa positive effect “wears-off” typically 
before the next dose). Ruottinen and Rinne observed that the 
addition of 200 mg of entacapone to each dose of levodopa/
carbidopa increased the “on” time (when patient experiences 
benefit from levodopa) by 2.5 hours and reduced by 16% 
the daily levodopa dose.6 In the SEESAW study, entacapone 
increased daily “on” time by 1 hour, decreased the daily 
levodopa dose by 12% and improved activities of daily liv-
ing (ADL), motor and total scores of the Unified Parkinson’s 
Disease Rating Scale (UPDRS).7 In the NOMECOMT study, 
the daily “on” time increased by 1.4 hours with levodopa 
daily dose reduction of 12%.8 This effect was sustained in a 
3-year open label extension of the study. In the CELOMEN 
study, the daily “on” time increased by 1.7 hours, the daily 
“off” time decreased by 1.5 hours, the mean daily levodopa 
dose was reduced by 54 mg, and the ADL, motor and total 
UPDRS scores improved.9 In the UK-IRISH study, the daily 
“on” time increased by 1.3 hours and the “off” time decreased 
by 1.1 hours.10
These results coupled with bioequivalence studies lead 
to CLE approval by the US Food and Drug Administra-
tion (FDA) in 2003 for substitution of carbidopa/levodopa 
(CL) and entacapone taken separately and for replacing 
CL in PD patients experiencing “wearing-off” signs and 
symptoms (for patients taking daily levodopa dose up to 
600 mg and not experiencing dyskinesia). The aim of this 
article is to review the evidence for safety, tolerability, 
efficacy and cost-effectiveness of CLE and its place in the 
treatment of PD.
Methods
We reviewed the literature by using the PubMed, Medline and 
Cochrane databases. We used the search terms “Stalevo” and 
“entacapone”. The search produced 21 articles about CLE in 
PubMed and Medline combined and zero articles in Cochrane 
database. Of these, 8 articles were foreign, could not be 
obtained, and were excluded. Of the remaining, 9 articles 
were original papers, 3 were review articles and 1 was an 
abstract about cost-effectiveness. We included unpublished, 
to this point, data from the STRIDE-PD study.
Disease overview
Parkinson’s disease is named after James Parkinson who 
published in 1817 a monograph with the title “An Essay on 
the Shaking Palsy”.11 The incidence of PD is about 14 per 
100,000 population per year overall but increases to 160 for 
the population aged 70 years or older. The median preva-
lence is 9.4 per 1000 with a 2% risk for developing PD by 
the age of 80. It affects approximately 1 million individuals 
in the USA.12,13 The mortality rate was reported to be 3-fold 
greater in PD patients before the introduction of levodopa. 
This was reduced to 1.6-fold in the post-levodopa era with 
a trend to increase again.14,15 The pathologic hallmark of PD 
is the loss of dopamine producing neurons in the substantia 
nigra (SN) accompanied by the intraneuronal accumulation 
of alpha-synuclein containing Lewy bodies (LB) resulting 
in dopamine deficiency.16,17 There is much research on the 
etiology and pathogenesis of PD. Although genetic causes 
account for only 10% of the cases, the discovery of gene 
products and their function gave us better insight as to the 
possible pathogenic mechanisms. In particular, the concept of 
protein mishandling seems important, and involves the ubiq-
uitin-proteasomal system and the lysosomes. Mitochondrial 
dysfunction, oxidative stress, apoptosis, and inflammation are 
also important mechanisms that possibly interact with each 
other.18–22 Environmental factors can have a harmful (like 
pesticides),23 or protective effect (cigarette smoking).24
PD typically has an asymmetric onset with bradykinesia, 
rest tremor, rigidity and postural instability being its cardinal 
motor features.22,25 Bradykinesia is the most characteristic 
manifestation of PD and presents with slowness of move-
ments resulting in loss of facial expression (hypomimia), Core Evidence 2010:5 
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low volume soft voice, reduced blinking, drooling and slow 
gait with poor arm swing. It is due to dopamine deficiency 
and failure of the positive feedback from the basal ganglia 
to the frontal cortex.26 Rest tremor is a 4 to 6 Hz oscillatory 
movement involving the distal parts of the extremities, such 
as hand (“pill-rolling” tremor) and foot. It is unilateral at 
onset and more prominent on the side it started when the 
disease progressively involves the other side. Interestingly, 
some patients report postural tremor years before the onset 
of PD.27 Rigidity is the resistance during passive movement 
of the limb, neck, or trunk. It may be associated with pain. 
Painful shoulder is a common initial manifestation of PD and 
usually misdiagnosed as of musculoskeletal origin.28 Postural 
instability is the loss of postural reflexes and usually occurs 
in later stages. It is demonstrated when a patient loses his 
balance while pulled forward or backward by the shoulders 
(“pull test”).26
In addition to the cardinal features, there are other motor 
manifestations of PD. Freezing is a sudden and transient loss 
of movement for a few seconds and typically involves the 
gait. It is a frequent cause of falls and can be only partially 
relieved by levodopa therapy. Other features are dysarthria, 
dysphagia, sialorrhea, decreased ocular convergence, and 
appearance of primitive reflexes, such as glabellar and pal-
momental.26
Nonmotor manifestations of PD are thought to be 
derived from neurotransmitter deficits other than dopamine, 
as opposed to most of the classic motor features.29,30 Those 
are categorized into neuropsychiatric, sleep, autonomic, 
and sensory symptoms. Neuropsychiatric manifestations 
include depression, anxiety, apathy, psychosis, and cogni-
tive impairment. Dysautonomia can manifest as orthostatic 
hypotension, hyperhidrosis, erectile dysfunction, constipation 
and bladder dysfunction. Finally, sensory symptoms take 
the form of olfactory dysfunction, akathisia, paresthesia, 
and pain.26,29,30
Current therapy options
Treatment for PD falls into three categories: therapies, 
medications and surgery. We will focus on the treatment of 
the cardinal motor features of PD, the majority of which are 
dopamine responsive. Physical and other therapies, surgery 
and the treatment of the nonmotor nondopamine responsive 
symptoms are beyond the scope of this article; the reader is 
referred to detailed reviews of these topics.22,31,32
The cardinal motor features of PD, bradykinesia and 
rigidity, respond very well to dopamine replacement 
treatment. Tremor can be less responsive, whereas postural 
instability shows the least response to dopaminergic 
strategies. Levodopa is the most effective medication and 
has been employed in the treatment of PD since the late 
1960s.1,33 Currently, we have a variety of dopaminergic and 
non-dopaminergic medications available. Dopaminergic 
agents are: dopamine precursor (levodopa), decarboxylase 
inhibitors (carbidopa, benserazide), dopamine agonists 
(pramipexole, ropinirole, pergolide, bromocriptine, apomor-
phine, cabergoline, lisuride), COMT inhibitors (entacapone, 
tolcapone), type B MAO inhibitors (selegiline, rasagiline) 
and dopamine releaser/anti-glutamergic (amantadine). Anti-
cholinergics have been used since the 1950s for symptomatic 
relief, due to their anti-muscarinic effect. However, they 
result in memory impairment and hallucinations, especially 
in the elderly. Therefore, they are rarely used. They are less 
effective than their dopaminergic counterparts. The most 
significant benefit is on tremor severity.22,31,32
Over time, treatment with levodopa is associated with 
“wearing-off” phenomenon (treatment effect wears off 
with return of parkinsonian symptoms) and dyskinesia 
(choreiform involuntary movements and dystonia). The 
ELLDOPA study showed a dose-response improvement in 
UPDRS scores, but also a dose-response effect regarding 
motor complications, with dyskinesia occurring in 16.5% and 
wearing-off in 28% of patients treated with daily levodopa 
dose of 600 mg for 9 months.34 On the other hand, the 
CALM-PD study compared pramipexole to levodopa with 
respect to their potential for developing motor complications. 
Pramipexole-treated patients had less incidence of dyskinesia 
(10% versus 31%) and wearing-off periods (24% versus 
38%) after 2 years.35 Pramipexole was less effective and 
associated with more somnolence than levodopa. Therefore, 
in early PD patients there is some debate about whether to 
initiate treatment with levodopa or dopamine agonists. In 
the treatment of moderate and more advanced disease non-
levodopa medications are not effective and the introduction 
of levodopa is required.22,31,32
Unmet needs
The major unmet need is the discovery of a neuroprotective 
treatment. To date, there is no definite evidence for any of 
the marketed medications to be neuroprotective. A detailed 
discussion is beyond the scope of this article and the reader 
is referred to relevant reviews.22,31
The management of motor complications (wearing-off 
and dyskinesia) poses significant problems in clinical prac-
tice. The pathogenesis of the motor complications is believed 
to be derived from the pharmacokinetics of the dopaminergic Core Evidence 2010:5 
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medications (especially levodopa) and the reduced 
dopamine-producing neurons in the substantia nigra (SN). 
Normally, the SN delivers dopamine to the striatum in a 
tonic, continuous manner. In PD patients we substitute the 
deficit in dopamine production with an intermittent pattern 
of delivery, owing to the short half-life of levodopa and the 
decreased buffering potential of the remaining functioning 
SN neurons. This nonphysiologic pattern results in postsyn-
aptic alterations that involve gene transcription and the firing 
pattern of the basal ganglia output neurons. Therefore, the 
current trend is to develop strategies that provide continuous 
dopaminergic stimulation.31
Clinical evidence with carbidopa/
levodopa/entacapone
In the first section we discussed the evidence for the use of 
entacapone. Entacapone has a similar pharmacokinetic profile 
to levodopa, and taken together increases levodopa’s half-
life and bioavailability. This approach leads to increasing 
the daily “on” time, decreasing the daily “off” time and the 
daily levodopa dose.6–10
A product that combines carbidopa, levodopa, and enta-
capone in one tablet should have similar pharmacokinetic 
and efficacy profile. However, the initial step is to prove bio-
equivalence between CL and entacapone taken separately and 
combined in one tablet. Four bioequivalence studies tested 
CLE at different doses (two with CLE containing 50 mg of 
levodopa, another with 100, and the fourth with 150 mg of 
levodopa per CLE tablet). There were 40 healthy volunteers 
per study. They used an open, randomized, crossover and 
replicate design. They administered either the test drug 
(CLE) or the reference drug (CL and entacapone) after an 
overnight fast. Fifteen blood samples were drawn at the same 
point in time for up to 12 hours after drug administration. 
Plasma concentrations of levodopa, carbidopa, and enta-
capone were measured. To determine bioequivalence they 
calculated the area under the concentration-time curve from 
0 up to 12 hours (AUC1–12 h), Cmax, tmax, and the elimination 
half-life for levodopa, carbidopa, and entacapone separately. 
The bioequivalence criteria were met for all three compo-
nents of all different CLE doses, the levodopa half-life for 
CLE being 1.7 hours (range 1.2 to 3.1 hours).36
Efficacy, safety, and tolerability
All the CLE studies that assessed efficacy, safety and toler-
ability will be analyzed. The endpoints for efficacy were the 
UPDRS, Parkinson’s Disease Questionnaire-39 (PDQ-39: 
including quality of life assessment), Parkinson’s Disease 
Questionnaire-8 (PDQ-8: quality of life), Clinical Global 
Impression (CGI for patients and investigators), Quality Of 
Life-Visual Analog Scale (QOL-VAS). Safety was assessed 
by the rate of adverse event (AE), and tolerability by the 
discontinuation rate.
The first study to assess safety and tolerability of CLE 
in PD patients was conducted by the SELECT-TC Study 
Group; an open-label, single-arm, 4-week investigation. 
They recruited PD patients, experiencing wearing-off, with 
or without mild dyskinesia. All were receiving a stable dose 
of immediate release formulation CL (25/100) for at least 
1 month prior to study entry. Patients were directly switched 
from immediate release CL to the equivalent dose of CLE. 
Tolerability was the primary endpoint. The secondary points 
were percentage with new onset dyskinesia and worsening 
of pre-existing dyskinesia. Safety assessments included 
adverse events and measurement of vital signs, EKG, physical 
examination, and blood and urine values. One hundred and 
sixty-nine patients were studied. The mean age was 66 years 
and mean disease duration was 5.23 years. The mean Hoehn 
and Yahr (H&Y) stage was 2.28 and 23% had mild dyskinesia 
at study entry. Eight percent of patients discontinued the 
study, the majority due to adverse events, including nausea, 
worsening of “off” periods, blurred vision, headache, vivid 
dreams, lightheadedness, and joint pain. Dyskinesia devel-
oped in 8.5% of subjects without history of dyskinesia and 
it worsened in 43.6% of those with pre-existing dyskinesia. 
The majority improved in their dyskinesia with or without 
reducing the CLE dose. All adverse events were mild and 
infrequent with nausea being the most frequent (in 12.4% of 
patents). No clinical relevant changes in vital signs or labora-
tory testing were noted.37 The conclusion was that the CLE 
was tolerated by subjects previously treated with immediate 
release formulation CL (25/100).
The TC-INIT study group conducted the first randomized, 
multinational, parallel-group clinical trial that compared 
the efficacy and safety of CLE to CL and entacapone in PD 
patients with end-of-dose wearing-off and a mean levodopa 
treatment duration of 5 to 6 years.38 They randomized 
77 patients to CLE and 88 to CL and entacapone. They used 
three different CLE doses: 50/12.5/200 mg, 100/25/200 mg 
and 150/37.5/200 mg (for levodopa/carbidopa/entacapone 
respectively). In both groups, the mean age of disease onset 
was 60 years, the mean disease duration was 6 years, the 
mean levodopa dose was 472 mg in the CL and entacapone 
and 493 mg in the CLE group and all patients had mild 
to moderately advanced disease (H&Y from 1 to 3). They 
all had wearing-off for at least 1 year and were on a stable Core Evidence 2010:5 
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dose of CL only, for at least 6 weeks prior to study entry. The 
study comprised a 2-week dose adjustment period, a 6-week 
treatment period and a 2-week follow up. Adverse events were 
reported by 55% of the total population without significant 
difference between treatment groups. 75% of the adverse 
events were classified by the patients as “mild”, 24% as 
“moderate” and 1% as “severe”. Nausea was the most com-
mon with a trend to be more frequent in the CLE group (14% 
versus 9%). Influenza-like symptoms were reported only to 
CLE group (7%), whereas dyskinesia was more common in 
the CLE group (7% versus 3%). Discontinuation rate was 5% 
in the CLE and 3% in the CL and entacapone group. Eighty 
percent of the patients responded that they preferred taking 
CLE compared with two separate tablets. The mean levodopa 
dose did not change significantly in either group compared 
with baseline. The primary efficacy variables were the CGI 
scores, UPDRS change in part III (motor performance), and 
the total levodopa dose at week 6. In respect to CGI score, 
73% of the patients in the CLE and 76% in the CL and enta-
capone group reported improvement. The investigator CGI 
scores improved in 79% of patients in both groups. UPDRS 
part III scores significantly improved in both the CLE and 
CL and entacapone groups (P  001 and P = 0.0016 respec-
tively). The QOL-VAS was significantly better in the CLE 
group compared with the CL and entacapone group. The 
conclusion of this trial was that both groups were effective 
and well tolerated.
Another study assessed the conversion from sustained 
release CL (SR-CL), or SR-CL and entacapone, or SR-CL 
and standard CL with or without entacapone to CLE. It was an 
open-label study with one month follow up. The conversion 
was done overnight. Each SR-CL 50/200 mg (carbidopa/
levodopa, respectively) converted to CLE 37.5/150/200 mg 
(carbidopa/levodopa/entacapone, respectively) and each 
SR-CL 25/100 mg to CLE 25/100/200 mg. They recruited 
62 PD patients with mean age of 67 years, disease duration 
of 11 years and daily levodopa dose of 670 mg. 80% of 
the patients were having wearing-off at baseline and 47% 
dyskinesia. 13 out of 62 patients (21%) withdrew before 
the end of the 1-month period due to adverse events. They 
were older than the CLE group who completed the study 
(73 versus 66 years) with longer disease duration (12.5 versus 
10 years). Withdrawals were due to nausea in 54%, increased 
“off” time in 38.5%, and dyskinesia, dizziness and insomnia 
in 23%. None of these subjects had been previously exposed 
to entacapone. Forty-nine patients completed the 1-month 
follow-up. Forty-two preferred CLE and 7 SR-CL. Adverse 
events were less frequent in the CLE than the SR-LC group. 
Twenty-one were taking entacapone at baseline. In these 
patients, there were significant improvements only in UPDRS 
motor scores, by 7 points. In the entacapone-naïve patients, 
there were significant improvements in UPDRS motor scores 
(by 4 points) and PDQ-39 activities of daily living (ADL) 
score by 6 points. 78.6% of the entacapone-naïve patients 
and 86% of the total study population preferred CLE over 
SR-CL. Those who preferred SR-CL were older (68.6 versus 
65.7 years) and had longer disease duration (11.7 versus 
10.0 years).39 The conclusion of this trial was that CLE was 
preferred by most patients to SR-CL.
The Simcom Study was a single group, open, crossover, 
multicenter, phase III study that assessed the switch from CL 
and entacapone to CLE. Fifty-two PD patients were included. 
Mean age was 61 years, age at onset of PD was 53 years, 
disease duration was 9 years, duration of levodopa treatment 
was 8 years, daily levodopa dose was 509 mg and duration 
of entacapone treatment was 2 years. It consisted of a 4 week 
control phase (patients continued their usual regimen), a 
4-week treatment phase (patients received CLE at equivalent 
dose) and a 2-week follow up period (patients returned to 
their baseline treatment). Efficacy parameters were patient 
preference, UPDRS and QOL-VAS scores. 54% of the 
patients preferred CLE compared with 31% who preferred 
the previous treatment (P = 0.162). 86% of all the levodopa 
doses were directly replaceable. UPDRS scores (part I for 
cognition and mood, part II for ADL and part III for motor 
performance) improved from a mean of 35.6 at baseline by 
2.5 points (P  0.01). UPDRS part III scores improved from 
24 by 1.9 points (P  0.01). The mean daily levodopa dose 
in the CLE group was lower by 24.6 mg (from 509 mg at 
baseline). There was no difference in the QOL-VAS score. 
Three patients (6%) discontinued due to adverse events. 
Seventeen out of 52 patients developed mild to moderated 
adverse events. Most common were dyskinesia, nausea, 
diarrhea, and influenza-like symptoms.40 The conclusion of 
this study was that some measures were improved on CLE 
compared with CL.
The Spanish Stalevo Study Group assessed whether or 
not the dose of levodopa should be reduced when switching 
from CL to CLE in patients with wearing-off and without or 
with mild dyskinesia at baseline in order to avoid emergence 
or worsening of dyskinesia. It was a multicenter, prospec-
tive, single-blind, randomized and clinically controlled 
4 week study. Thirty nine patients were randomized to either 
group A (receiving the same dose of levodopa in the form of 
CLE) or group B (reducing the dose of levodopa contained 
in CLE by 15% to 25%). Efficacy endpoints were UPDRS, Core Evidence 2010:5 
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PDQ-39, CGI change and home “on-off” diaries. Mean age 
was 68 years in group A and 67 in group B. PD duration was 
8.5 and 9.4 years, levodopa duration 7.5 and 8.7 years with a 
daily dose of 566 mg and 670 mg respectively. H&Y stage 
was II to III in 75% of the patients, but more patients with 
stage IV were in group A. UPDRS total score at baseline was 
55 in group A and 58 in B. Seven patients in group A and 
eight in group B had dyskinesia at baseline. Six patients in 
group A (35%) and 5 in group B (22.7%) experienced mild 
and transient adverse events. Nausea, dizziness, somnolence, 
and abdominal pain were the most common. One patient in 
group A discontinued due to increased dyskinesia. Objec-
tive increase of dyskinesia was documented in two patients 
in each group. Group A patients experienced a significant 
increase in “on” time of 76 minutes and significant decrease 
on “off” time of 123 minutes. Group B experienced a modest 
increase in “on” time of 38 minutes and decrease in “off” time 
of 32 minutes. The daily “on” with dyskinesia increased by 
33 minutes in group A and by 98 minutes in group B. Total 
UPDRS score improved by 1 point in “on” state and 6 points 
in “off” state in group A, and by 3 and 5 points respectively 
in Group B. PDQ-39 and CGI results regarding quality of life 
did not change significantly, but more than 60% of patients 
felt better in both groups. Dyskinesia was not a major prob-
lem in this study. The conclusion of this study was that there 
was no advantage to reducing the dose of levodopa when 
switching to CLE.41
The START-M open 6 week trial assessed the efficacy, 
safety and tolerability of CLE when PD patients with wearing 
off switched from CL. Fifty patients were included with a 
mean age of 66.7 years, mean disease duration of 6.8 years 
and a mean daily levodopa dose of 540 mg. 38% of patients 
had H&Y stage 2 (bilateral parkinsonism without postural 
instability), 41% stage 2.5 (bilateral disease and instability 
with recovery on pull test) and 32% stage 3 (bilateral disease 
with instability and no recovery on pull test). Twenty-seven 
percent of the patients had dyskinesia. The daily levodopa 
dose in the form of CLE was equivalent to the baseline dose. 
Assessment tools were the UPDRS score, motor fluctua-
tion questionnaire and CGI scores. By week 6 there was a 
significant (P  0.001) reduction of the total UPDRS score 
from 46.5 to 36 points (29% reduction). Subscale reductions 
(mean) were as follows: part I by 1.1 points (30%), part II 
by 3.6 points (25%) and part III by 4.8 points (24.7%). 
Mean daily “off” time reduced by 1.7 hours. Improvement 
rate based on CGI was 52% (patient assessment) and 72% 
(physician assessment). Fewer than 10% of patients experi-
enced side effects, mainly nausea, orthostatic dizziness and 
headache. None of them required intervention.42 This open 
trial showed improvements on many measures when patients 
switched to CLE.
The QUEST-AP study group addressed the question 
whether CLE treatment improved quality of life when com-
pared with CL treatment in PD patients without or with mini-
mal, nondisabling motor fluctuations. It was a randomized, 
double-blind, parallel-group, active-controlled multicenter 
12-week trial. Inclusion criteria were PD patients with H&Y 
stage of 1 to 2.5, with 0 to 3 hours of non-disabling daily 
“off” time and total daily levodopa dose between 300 mg 
and 800 mg for at least 1 month prior to study entry. Patients 
with dyskinesia were excluded. The primary outcome was 
a change in the total PDQ-8 score. PDQ-8 is a motor and 
non-motor eight domain questionnaire ranging from 0 (no 
impairment) to 32. It is highly correlated with the PDQ-39 
assessment tool. Secondary outcome measures were the 
UPDRS (parts I, II, III and IV) scores and the proportion of 
patients experiencing wearing off periods. Seventy percent 
had no fluctuations at baseline and 30% had non-disabling 
motor complications (UPDRS part IV score was only 1.3 of 
a maximum of 23). One hundred and eighty four patients 
were randomized to either CLE or CL treatment groups in 
a 1:1 ratio. They found a 1.4 point difference in the PDQ-8 
score favoring CLE treatment (P = 0.41). UPDRS part II 
score improved in CLE group (P = 0.032) and part III score 
improved in both groups. The percentage of patients report-
ing at least one wearing off symptom dropped from 78.5% to 
62% in the CLE group and from 84.5% to 61.5% in the CL 
group. The difference between groups was not significant. 
Fourteen patients (7.6%) discontinued the study, six in CLE 
and four in the CL groups. At least one adverse event was 
reported by 66% and 56% of patients in the CLE and CL 
group respectively. More common adverse events were urine 
discoloration, nausea, dizziness, constipation, and diarrhea. 
Mild dyskinesia was reported in 5 patients in the CLE group 
(5.4%) and 1 patient in the CL group (1.1%).43 This study 
failed to show its primary outcome.
The FIRST-STEP study group evaluated the safety, toler-
ability and efficacy of CLE compared with CL in early PD 
patients warranting levodopa treatment. It was a 39-week, 
multicenter, randomized, double-blind, parallel-group study. 
Eligible patients needed to have UPDRS part II plus part III 
scores of more than 18 points and H&Y stage 1–2.5. Patients 
with more than 5-year disease duration were excluded. Mean 
age was 65 years, mean disease duration 1.16 years and mean 
UPDRS (part II and III) score was 34. Only 2.4% of patients 
were on levodopa, 8% on dopamine agonists, and 34% on Core Evidence 2010:5 
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other PD medications. They were randomized 1:1 to CLE 
(25/100/200) mg 3 times daily (tid) or CL (25/100) mg tid. 
Primary outcome was the change in UPDRS (part II and 
III) scores. Secondary outcomes were the change in UPDRS 
subscale scores, PDQ-39 and PDQ-8 scores, H&Y stage, 
Schwab and England (S + E) ADL score, and CGI scores. 
Treatment success was defined as a reduction of UPDRS 
total score of more than 8 points. The mean change in total 
UPDRS score was 10 points in the CLE and 8.5 points in 
the CL group favoring CLE (P = 0.045). Secondary efficacy 
results showed greater improvement with CLE in UPDRS 
ADL (part II) subscale by 3 points (P = 0.025), S+E scores 
by 5.6 points (P = 0.003) and patient CGI (P = 0.047). No 
significant change noted in UPDRS part III (motor score), 
PDQ-39, PDQ-8 and H&Y stage. Interestingly, there was no 
significant change in the incidence of dyskinesia and off-time 
between groups. Dyskinesia was observed in 11 (5.3%) 
subjects in the CLE and 16 (7.4%) in the CL group. Twenty-
four patients (11.6%) in the CLE and eighteen (8.4%) in the 
CL group discontinued due to AE. The incidence of AE was 
higher in the CLE (82%) than the CL (60%) group. Nausea 
and diarrhea were the most common.44 The primary outcome 
was achieved in this trial.
The STRIDE-PD study evaluated whether CLE would 
delay the onset of dyskinesia compared with CL in patients 
with early PD requiring levodopa treatment. In this multi-
center study, 747 patients were randomized to either CLE 
25/100/200 mg or CL 25/100 mg with dosing every 3.5 hours 
and up to 400 mg of daily levodopa dose. Treatment dura-
tion was variable between 134 and 208 weeks. The primary 
endpoint was the time to onset of dyskinesia. It was reported 
that patients treated with CLE had shorter time to dyskinesia 
and higher incidence of dyskinesia.45 Therefore, the study 
did not achieve its goal.
Cost effectiveness
In one study conducted in the UK, cost-effectiveness of 
CLE was compared to standard care in PD patients with 
wearing-off using the Markov model. The costs and outcomes 
of both treatments were projected over a period of 10 years. 
Sensitivity analyses were used to assess the confidence level 
of the results. CLE produced a reduction in the total 10-year 
direct cost to society of  10,198 per patient. The Monte 
Carlo sensitivity analysis indicated that the likelihood of 
CLE being either “dominant” (ie, better clinical outcome 
with lower cost) or more effective at an acceptable cost was 
93% even when all uncertainties associated with the model 
were taken into account. When compared to standard care, 
the probability that CLE would be cost-effective to the society 
as a whole was 77%.46 We should interpret the results of this 
study with caution as to its ability to be generalized to other 
countries.
Patient group/population
The population in the CLE studies consisted mainly of PD 
patients with early to moderately advanced disease, with 
non-disabling wearing-off symptoms and mild, if at all, 
dyskinesia. This is particularly true for the studies that com-
pared CL to CLE, either on direct switch from the former to 
the latter,41,42 or comparing directly the two treatments.43,44 
The mean disease duration ranged from 1.16 to 9 years. The 
H&Y stage ranged from 1 (unilateral disease) to 3 (bilat-
eral disease with postural instability). The only study that 
included more advanced patients was the one that assessed 
switching from SR-CL to CLE.39 This study’s population 
were patients with disease duration of more than 10 years, 
with 80% experiencing wearing-off and 47% dyskinesia at 
baseline. Those being naïve to entacapone had higher AE 
and discontinuation rates.
Dosage, administration, 
and formulation
CLE tablets are taken orally and are available in different 
strengths (numbers in mg correspond to carbidopa/levodopa/
entacapone dose, respectively):47
  12.5 mg/50 mg/200 mg
  18.75 mg/75 mg/200 mg
  25 mg/100 mg/200 mg
  31.25 mg/125 mg/200 mg
  37.5 mg/150 mg/200 mg
  50 mg/200 mg/200 mg
Place in therapy
In all the clinical trials so far, CLE exhibits a favorable 
efficacy, safety and tolerability profile, equivalent to the 
entacapone studies. However, there was a greater incidence 
of “dopaminergic” side effects in patients taking CLE com-
pared with CL, with nausea being the most frequent. They 
were rated as mild and easily manageable in the majority 
of the cases. The discontinuation rate and incidence of 
adverse events seem to be more prominent in older patients, 
naïve to entacapone with more advanced disease, longer 
disease duration and higher daily levodopa dose.39 Although 
the FIRST-STEP study results showed no statistically differ-
ent rate of dyskinesia between CLE and CL groups in early 
PD patients, unpublished data from the STRIDE-PD study Core Evidence 2010:5 
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reported that early PD patients treated with CLE are likely 
to develop dyskinesia sooner and at a higher rate than the 
ones treated with CL.44,45 Of note is the fact that these are the 
only long term studies so far.
Efficacy, safety and tolerability outcomes along with the 
population characteristics suggest that CLE is a safe treat-
ment with a mild side effect profile. It improves quality of 
life, decreases mean daily “off” time and increases daily “on” 
time in PD patients with moderately advanced disease and 
non-disabling “wearing-off” without or with mild dyskinesia. 
Patients can be switched directly from CL with or without 
entacapone without having to decrease the levodopa dose. 
CLE is more convenient for the patients and preferred by the 
majority of them. There is also evidence in one study that it 
is feasible to switch from SR-CL to CLE.39
CLE cannot be recommended in early PD patients 
to prevent the development of dyskinesia. It should not 
be considered in patients with disease duration greater 
than 10 years, significant wearing-off with troublesome 
dyskinesia and whose total daily levodopa dose is more than 
600 mg.39,45
There is no evidence to support a favorable cost-
effectiveness profile for CLE. The one well conducted study 
concluded that CLE is cost-effective.46 However, we have to 
take into consideration that this study was conducted in the 
UK where a national health service is in place. Therefore, 
its results may not reflect the intricacies of different health 
care systems.
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